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Abstract 
Nowadays cancer remains one of the main causes of death in the world. Current diagnostic 
techniques need to be improved to provide earlier diagnosis and treatment. Traditional therapy 
approaches to cancer are limited by lack of specificity and systemic toxicity. In this scenario na-
nomaterials could be good allies to give more specific cancer treatment effectively reducing un-
desired side effects and giving at the same time accurate diagnosis and successful therapy. In this 
context, thanks to its unique physical and chemical properties, graphene, graphene oxide (GO) and 
reduced graphene (rGO) have recently attracted tremendous interest in biomedicine including 
cancer therapy.  
Herein we analyzed all studies presented in literature related to cancer fight using graphene and 
graphene-based conjugates. In this context, we aimed at the full picture of the state of the art 
providing new inputs for future strategies in the cancer theranostic by using of graphene.  
We found an impressive increasing interest in the material for cancer therapy and/or diagnosis. 
The majority of the works (73%) have been carried out on drug and gene delivery applications, 
following by photothermal therapy (32%), imaging (31%) and photodynamic therapy (10%). A 27% 
of the studies focused on theranostic applications. Part of the works here discussed contribute to 
the growth of the theranostic field covering the use of imaging (i.e. ultrasonography, positron 
electron tomography, and fluorescent imaging) combined to one or more therapeutic modalities. 
We found that the use of graphene in cancer theranostics is still in an early but rapidly growing 
stage of investigation. Any technology based on nanomaterials can significantly enhance their 
possibility to became the real revolution in medicine if combines diagnosis and therapy at the same 
time. We performed a comprehensive summary of the latest progress of graphene cancer fight and 
highlighted the future challenges and the innovative possible theranostic applications. 
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Introduction 
Despite the everyday progresses of medicine 
solutions for human health, today cancer is still one of 
the biggest challenges for humanity. Thanks to the 
advancements in prevention and in treatment, the 
survival rate has been improved in the last few years. 
However, cancer remains one of the main causes of 
death worldwide with 8,2 million of death occurred in 
2012. It is estimated that by 2020, there will be be-
tween 15 and 17 million new cases of cancer every 
year, 60% of which will be in developing countries [1]. 
In economical developed countries the burden of 
cancer is a result of population aging and growth as 
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well as an increasing adoption of cancer-associated 
lifestyle choices including smoking, physical inactiv-
ity, and ‘‘westernized’’ diets [2, 3]. Cancer, as defini-
tion, is the uncontrolled growth of cells that can occur 
in any type of tissue and, at the late stage, these cells 
lose their adhesion capacities and migrate to healthy 
tissues. Other than surgical treatment, the different 
options are all based on a mechanical or pharmaco-
logical killing action against cancer cells, possibly 
avoiding the side effect damages of healthy cells.  
Nanotechnology is one of the best promises to 
attack cancer cells more specifically, effectively and to 
reduce undesired side effects. In other terms, nano-
technology can be used to transport drugs to a specific 
site using specific keys such as antibodies. Moreover, 
in the context of developing innovative theranostics, 
nanomaterials could be used for imaging as a diag-
nostic tool and, at the same time, to stimulate and 
control the release of drugs in the cancer site.  
In the recent years numerous nanomaterials 
have been explored for potential theranostic applica-
tions for cancer therapy thanks to their properties [4].  
Compared to traditional molecular contrast 
agents or drugs, nanomaterials can be engineered to 
improve and integrate multiple functions in a single 
system also to give the control of drugs release, being 
of hope for the building of a next generation of anti-
cancer tools [5].  
The relatively new nanomaterial, graphene, has 
attracted tremendous interest in the scientific com-
munity and in the public [6-9] being explored for 
many potential applications due to its unique physi-
co-chemical characteristics including electronic, opti-
cal, thermal and mechanical properties [10-12]. The 
precise structure of graphene has been the subject of 
debate over the years since it varies greatly with the 
preparation methods and extent of oxidation [13, 14]. 
Nevertheless, graphene can be rich in functional 
groups such as carboxylic and hydroxyl groups which 
facilitate its surface modifications. Very recently, 
graphene and graphene oxide (GO) have been inves-
tigated in a growing number of medical applications, 
such as drug delivery, diagnostics, tissue engineering 
and gene transfection all with the final aim to use it as 
a theranostic materials [15-18]. However, one of the 
main concerns of using graphene in nanomedicine is 
its biocompatibility. Similarly to many other nano-
materials, it is necessary to carefully address its bio-
degradability in aqueous solutions. In addition, the 
dimensions of the flakes of graphene could be re-
sponsible of different impacts on cell viability [19]. On 
the other hand, specific toxic effects of graphene on 
cancer cells could represent a positive point. Indeed, 
many reports have shown that this function of gra-
phene could be useful in possible future therapeutic 
applications [20, 21], for example as an inhibitor of 
cancer cell metastasis [22]. Furthermore, different an-
ticancer biomolecules such as siRNA, DNA and other 
drugs can be loaded onto the graphene surface for 
gene silencing and transfection, drug delivery and 
many other cancer therapy applications [23]. 
In this review we analyzed all studies presented 
in literature aiming to fight cancer using graphene 
and graphene-based conjugates. We found that the 
graphene strategies in fighting cancer can be summa-
rized in 4 main groups: i) drug delivery, ii) photo-
thermal therapy (PTT), iii) photodynamic therapy, 
(PDT) and iv) imaging. Furthermore, we evidenced 
the works where authors used diagnostic and differ-
ent therapy strategies such as drug delivery into one 
system promoting the use of graphene as a theranostic 
tool. We also carefully evaluated the use and the im-
pact of graphene by tumor type. Our purpose was to 
broaden the knowledge of graphene as useful tech-
nology for the future of clinical cancer treatment and 
diagnosis. In this work we point out what are the 
lacking areas of graphene investigation from an on-
cology point of view, underling what can be the most 
promising approaches for the use of graphene-based 
tools in the challenging field of cancer. 
Studies selection criteria and overview 
To achieve our aim, we performed a “PubMed 
search” using the following keywords: graphene, 
graphene oxide, cancer therapy, drug delivery and 
cancer, immunotherapy, imaging and cancer, cancer 
diagnosis. The keyword exploration was done in 
several different combinations. High impact review 
articles also served as additional tool. The list of re-
ported studies includes all the retrieved publications 
from 2008 to November 2014. In table 1 we report a 
characterization of all the studies based on: type of 
application, type of cancer, species, model, type of 
graphene in terms of functionalization, year of publi-
cation and reference.  
 
Table 1. Functionalized graphene. 
Type of applications Type of cancer Tumor-cell 
type 
Model  Drug/Imaging molecules 
used 
Graphene Year  Reference 
Drug Delivery and Imaging Burkitt's Lym-
phoma 
Human In Vitro Doxorubicin, Rituxan Fluo-
rescence Imaging 
nGO-PEG 2008 Sun X. et al (Nano Res.) 
 Imaging and Photothermal 
Therapy 
Breast Cancer Mouse In Vivo Fluorescence Imaging nGS-PEG 2010 Yang K. et al (Nanoletters) 
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Drug Delivery Breast Cancer Human In Vitro Doxorubicin and Camptothe-
cin 
nGO-Acid Folic 2010 Zhang L. et al (Small) 
Drug Delivery Breast Cancer Human In Vitro Camptothecin GO-PVA 2011 Sahoo N.G. et al (Chem. 
Comm.) 
Drug Delivery Breast and Colon 
Cancer 
Human In Vitro Maltodextrin (MD) and EA 
(ellagic acid) 
GO-Pluronic F38, 
GO-Tween 80, GO-MD 
and EA  
2011 Kakran M. et al (Curr. Med. 
Chem.) 
Gene Delivery and Imaging Cervical and 
Prostate Cancer 
Human In Vitro pDNA (pCMV-Luc), Fluores-
cence Imaging 
GO-BPEI 2011 Kim H. et al (Bioconjug Chem.) 
Drug Delivery and Photo-
thermal Therapy 
Breast Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
Doxorubicin nGO-PEG  2011 Zhang W. et al (Biomaterials) 
Drug Delivery and Photo-
dynamic Therapy 
Cervical Cancer Human In Vitro Chlorin e6 GO-PEG 2011 Tian B. et al (ACS Nano) 
Photodynamic Therapy Gastric Cancer Human In Vitro   GO-Folic Acid (FA) 2011 Huang P. et al (Theranostics) 
Photothermal Therapy Brain Cancer Human In Vitro   nano-rGO-PEG and RGD 2011 Robinson J.T. et al (J. Am. 
Chem. Soc.) 
 Imaging and Photothermal 
Therapy 
Breast Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
Fluorescence Imaging rGO-QD (semiconductor 
quantum dots) 
2012 Hu S.H. et al (Adv. Mater.) 
 Imaging and Photothermal 
Therapy 
Breast Cancer Mouse In Vivo Fluorescence, Photoacoustic, 
and MR imaging 
rGO and rGO–iron 
chloride hexahydrate 
2012 Yang K. et al (Adv. Mater.) 
Drug Delivery Brain Cancer Human In Vitro 1,3-bis(2-chloroethyl)-1-nitroso
urea (BCNU) 
GO-PAA  2012 Lu Y.J. et al (Int. J. Nanomedi-
cine) 
Drug Delivery Breast Cancer Human In Vitro Doxorubicin GN-PF127 (Pluronic 
F127)  
2012 Hu H. et al (J. Biomed. Mater. 
Res. A) 
Drug Delivery Breast Cancer Human In Vitro Adryamicin GO 2012 Wu J. et al (Nanotechnology) 
Drug Delivery Breast Cancer Human In Vitro β-Lapachone rGO-Fe3O4  2012 Zheng X.T. et al (Mol. Pharm.) 
Drug Delivery Cervical Cancer Mouse In Vitro Doxorubicin NGs 2012 Yang Y. et al (Chemistry) 
Drug Delivery Cervical, Breast 
and Lung Cancer 
Human and 
Mouse 
In Vitro and 
In Vivo 
Tamoxifen Citrate NGs 2012 Misra S.K. et al (Small) 
Drug Delivery Liver Carcinoma Human In Vitro Elsinochrome A and Doxoru-
bicin 
rGO 2012 Wei G. et al (Chemistry) 
Drug Delivery and Imaging Breast Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
TRC105, Positron Emission 
Tomography  
GO 2012 Hong H. et al (ACS Nano) 
Imaging Breast Cancer Human In Vitro Fluorescence Imaging GO-Fe3O4(Fe)-PAMAM-
G4-NH2-Cy5 
2012 Wate P.S. et al (Nanotechnol-
ogy) 
Photothermal Therapy Breast Cancer Mouse In Vivo   nGO-PEG 2012 Yang K. et al (Biomaterials) 
Photothermal Therapy Colon Cancer Human In Vitro   GT-rGO  2012 Abdolahad M et al. (Mater. Sci. 
Eng. C Mater. Biol. Appl.) 
 Imaging and Photothermal 
Therapy 
Breast Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
Photoacoustic imaging rGO 2013 Sheng Z. et al (Biomaterials) 
 Imaging and Photothermal 
Therapy 
Cervical Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
US imaging and X-ray CT 
imaging 
GO-Au@PLA 2013 Jin Y. et al (Biomaterials) 
Drug Delivery Brain Cancer Mouse In Vitro Camptothecin GO-PDEA  2013 Kavitha T. et al (Phys. Chem. 
Chem. Phys.) 
Drug Delivery Brain Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
Doxorubicin GO-PEG-Tf (Transferrin) 2013 Liu G. et al (ACS Appl. Mater. 
Interfaces) 
Drug Delivery Brain Cancer Human In Vivo Epirubicin NMGO-PEG 2013 Yang H.W. et al (Adv. Mater.) 
Drug Delivery Breast Cancer Human In Vitro Hematin-terminated dextran 
and Doxorubicin 
GO 2013 Jin R. et al (ACS Appl. Mater. 
Interfaces) 
Drug Delivery Breast Cancer Human In Vitro Doxorubicin GQDs 2013 Wang C. et al (Sci. Rep.) 
Drug Delivery and Gene 
Delivery 
Breast Cancer Human In Vitro Adryamicin, siRNA (an-
ti-miR-21) 
GO-PEI-PSS 2013 Zhi F. et al (Plos One) 
Drug Delivery Cervical Cancer Human In Vitro Doxorubicin rGO-PEG-BPEI 2013 Kim H. et al (ACS Nano) 
Drug Delivery Cervical Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
Doxorubicin GO-PEG-Tf (Transferrin) 2013 Liu C.W. et al (Biomacromol-
ecules) 
Drug Delivery Cervical Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
Doxorubicin rGO-CHA (cholesteryl 
hyaluronic acid)  
2013 Miao W. et al (Biomaterials) 
Drug Delivery Liver Carcinoma Human In Vitro 5-fluorouracil MGNs 2013 Fan X. et al (Nanoscale) 
Drug Delivery Lung Cancer Human In Vitro Paclitaxel GO 2013 Arya N. et al (Nanoscale) 
Gene Delivery Skin Cancer Mouse In Vivo Stat3-specific siRNA GO-PEI-PEG 2013 Yin D. et al (Nanotechnology) 
Drug Delivery and Imaging Breast Cancer Human and 
Mouse 
In Vitro, In 
Vivo and Ex 
Vivo 
TRC105, Positron Emission 
Tomography 
rGO 2013 Shi S. et al (Biomaterials) 
Drug Delivery and Imaging Cervical Cancer  Human In Vitro Doxorubicin, Fluorescence 
Imaging 
GO-QDs 2013 Chen M.L. et al (Bioconjug. 
Chem.) 
Drug Delivery and Imaging Liver Carcinoma Human In Vitro Doxorubicin, MR Imaging GO-DTPA-Gd (diethy-
lenetriaminepentaacetic 
acid-gadolinium) 
2013 Zhang M. et al (ACS Appl. 
Mater. Interfaces) 
Drug Delivery and Photo-
dynamic Therapy 
Skin cancer Mouse In vitro and 
In Vivo 
Doxorubicin, Chlorin e6 GO 2013 Miao W. et al (Biomaterials) 
Drug Delivery and Photo-
thermal Therapy 
Brain Cancer Human In Vitro Doxorubicin GSPI (silica-coated 
graphene nanosheet) 
2013 Wang Y. et al 
(J.Am.Chem.Soc.) 
Drug Delivery and Photo-
thermal Therapy 
Brain Cancer Mouse In Vitro Epirubicin GO-PEG-EGFR 2013 Yang H.W. et al (Biomaterials) 
Photothermal, Photody-
namic Therapy and Imaging 
Breast Cancer Human and 
Mouse 
In Vitro, In 
Vivo and Ex 
Vivo 
Upconversion luminescence 
imaging 
GO-UCNPs--ZnPc 2013 Wang Y. et al (Biomaterials) 
Drug Delivery and Photo-
thermal Therapy 
Cervical and Lung 
Cancer 
Human In Vitro Doxorubicin GO 2013 Qin X.C. et al (J Photochem 
Photobiol B.) 
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Drug Delivery and Photo-
thermal Therapy 
Prostate Cancer Mouse In Vitro Doxorubicin, CGN (thermo-
sensitive nanogel) 
rGO  2013 Wang C. et al (Nanomedicine) 
Imaging Breast Cancer Mouse In Vivo Computed Tomography  GO 2013 Cornelissen B. et al (Bio-
materials) 
Photothermal and Photody-
namic Therapy 
Cervical Cancer Human In Vitro and 
In Vivo 
  GO 2013 Sahu A. et al (Biomaterials) 
Photothermal Therapy Breast and Lung 
Cancer 
Human In Vitro    rGO-Cu2O Nanocrystal 2013 Hou C. et al (Nanoscale) 
Photothermal Therapy Cervical Cancer Human and 
Mouse 
In Vitro, In 
Vivo and Ex 
Vivo 
  GO-IONPs-Au-PEG 2013 Shi X. et al (Biomaterials) 
Drug Delivery and Imaging Lung and Prostate 
Cancer 
Human and 
Mouse 
In Vitro and 
In Vivo 
Doxorubicin and 
GFP-plasmid, Fluorescence 
Imaging 
CMG (Chitosan Magnet-
ic-Graphene) 
2013 Wang C et a. (J. Mater. Chem. 
B Mater. Biol. Med.) 
Drig Delivery and Imaging Liver Cancer Human In Vitro Doxorubicin, MR imaging and 
Fluorescence imaging 
GO-SiO2  2013 Gao Y et al (Colloids Surf. B 
Biointerfaces) 
Gene Delivery and Photo-
thermal Therapy 
Cervical and 
Breast Cancer 
Human In Vitro siRNA targeting Plk1 mRNA  GO-PEG-PEI  2013 Feng L et al (Small) 
Drug Delivery Breast Cancer Human In Vitro Anastrozole GO-IOF/IOI/IO 2014 Chaudhari N.S. et al (Mater. 
Sci. Eng. C Mater. Biol. Appl.) 
Drug Delivery Breast Cancer Human In Vitro Camptothecin GO-cyclodextrin, hyalu-
ronated adamantane  
2014 Zhang Y.M. (Chem. Comm.) 
Drug Delivery Breast and Pan-
creatic Cancer 
Human In Vitro Gambocic Acid Gs/SWCNTs  2014 Saeed M.L. et al (J Appl Toxi-
col.) 
Drug Delivery Cervical Cancer Human In Vitro Camptothecin GO-PVCL 2014 Kavitha T. et al (Colloids Surf 
B Biointerfaces) 
Drug Delivery Cervical Cancer Human In Vitro Curcumin, Paclitaxol, Camp-
tothecin and Doxorubicin 
NGs-nile red and 
C–folate. 
2014 Maity A.R. et al (Nanoscale) 
Drug Delivery Cervical Cancer Human In Vitro Doxorubicin GO-PEI  2014 Chen H. et al (ACS Appl. 
Mater. Interface)  
Gene Delivery Colon Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
dsDNA GO 2014 Joseph D. et al (ACS Appl. 
Mater. Interfaces) 
Drug Delivery Glioblastoma and 
Breast Cancer 
Human and 
Mouse 
In Vitro Lucanthone  GO-PEG-DSPE 2014 Chaudhary S.M. et al (Nano-
medicine) 
Drug Delivery Liver Carcinoma Human In Vitro Camptothecin GO  2014 Yang X. et al (Nanoscale) 
Drug Delivery Liver Carcinoma Human and 
Mouse 
In Vitro and 
in Vivo 
Doxorubicin GO-HA (hyaluronic 
acid)  
2014 Song E. et al (ACS Appl. 
Mater. Interfaces)  
Drug Delivery Liver Carcinoma Human In Vitro Doxorubicin GO-PEG-alginate 2014 Zhao X. et al (Langmuir) 
Drug Delivery Lung Cancer Human In Vitro Paclitaxel GO-PEG 2014 Xu Z. et al (ACS Appl. Mater. 
Interfaces) 
Drug Delivery and Imaging Cervical Cancer Human In Vitro Doxorubicin, Fluorescence 
Imaging 
GO Capped Mesoporous 
Silica 
2014 He D. et al (Langmuir) 
Drug Delivery and Imaging Colon Cancer Human In Vitro and 
in Vivo 
Curcumin NGs Quantum Dot  2014 Some S. et al (Sci. Rep.) 
Drug Delivery and Imaging Liver Carcinoma Human In Vitro Curcumin, Optical Imaging GO-RGD-Chitosan 2014 Wang C. et al (Colloids and 
Surf. B Biointerfaces)  
Drug Delivery and Photo-
dynamic Therapy 
Lung Cancer Human In Vitro Hypocrellin A and Camptoth-
ecin 
rGO 2014 Zhou L. et al (J. Photochem. 
Photobiol. B) 
Drug Delivery and Photo-
thermal Therapy 
Breast Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
Doxorubicin GO-Au 2014 Shi J. et al (Biomaterials) 
Drug Delivery and Photo-
thermal Therapy 
Cervical Cancer Human and 
Mouse 
In Vitro and 
In Vivo 
Doxorubicin PEG-GO/Cus 2014 Bai J. et al (Biomaterials) 
Drug Delivery and Photo-
thermal Therapy 
Cervical Cancer Human In Vitro Doxorubicin rGO Capped Mesopo-
rous Silica 
2014 Wan H. et al (Nanoscale) 
Drug Delivery, Imaging and 
Phototermal Therapy  
Breast Cancer Human In Vitro Doxorubicin NGsAu nanocrystal 2014 Bian X. et al (Sci. Rep.) 
Imaging Breast Cancer Human In Vitro Colorimetric Assay GO-PtNPs (porous 
platinum nanoparticles) 
2014 Zhang L.N. et al (Anal. Chem.) 
Photodinamic Theraphy and 
Imaging 
Cervical Cancer Human In Vitro Fluorescence Imaging NGs-QDs 2014 Ge J. et al (Nat Commun.) 
Photothermal Theraphy and 
Imaging 
Pancreatic cancer Human In Vitro and 
In Vivo 
MR imaging GO-ION 2014 Wang S. et al (Biomaterials) 
Photodynamic Therapy Breast Cancer Mouse In Vitro   GO-PEG 2014 Rong P. et al (Theranostics) 
Photothermal, Photody-
namic Therapy and Imaging 
Cervical Cancer Human In Vitro Fluorescence and MR imaging MFG (magnetic and 
fluorescent graphene) 
2014 Gollavelli G. et al (Biomateri-
als) 
Photothermal Theraphy and 
Imaging 
Breast Cancer Human In Vitro Reman Imaging GO and GOAuNS 2014 Nergiz S.Z. et al (ACS Appl. 
Mater. Interfaces) 
Photothermal Therapy Epidermoid Car-
cinoma 
Human and 
Mouse 
In Vitro and 
In Vivo 
  GO-PEG-AuNR  2014 Dembereldorj U. et al (Photo-
chem Photobiol) 
Drug Delivery and Imaging Glioma Human In Vitro Doxorubicin, MR imaging MGSPI(Magnetic gra-
phene mesoporous silica) 
2014 Wang Y. et al (Small) 
Drug Delivery Colon Cancer Mouse In Vitro and 
In Vivo 
Doxorubicin, Camptothecin, 
Oxaliplatin and Cisplatin 
GO 2014 Chen GY et al (Biomaterials) 
Drug Delivery and Photo-
thermal Therapy 
Breast Cancer Human In Vitro Doxorubicin GO-PEG-DA 
(2,3-dimethylmaleic 
anhydride) 
2014 Feng L et al (Adv. Healthc. 
Mater.) 
Photothermal Therapy Gastric Cancer Human In Vitro   rGO, GO 2014 Li J.L. et al (J Biomed Mater 
Res A.) 
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The trend (Figure 1), from 2008 to 2014, shows an 
impressive increasing interest in graphene for cancer 
therapy; i.e. the number of publications in 2013 and 
2014 triplicated from 2012. Focusing on the type of 
application, we found that the majority of the works 
(73%) have been carried out on drug delivery and 
gene delivery (Figure 2A). The potential to act as a 
delivery tool against tumor cells seems to be one of 
the most attractive areas for scientists. In particular, 
compared to carbon nanotubes [24-26], graphene has 
two exposed side surface and, thus, at least a double 
external surface area than nanotubes that improve the 
conjugation capacity [27]. The particular arrangement 
of carbon atoms favors the non covalent complexation 
of drugs onto its surface, making possible a better 
release of drugs to the targeted cells. This characteris-
tic can be one of the reasons why graphene has raised 
great success in drug delivery applications for cancer 
therapy. Intriguingly, part of the studies used GO for 
drug delivery combined with other purposes, such as 
imaging, acquiring the ability to perform and follow 
the drug release.  
 
 
Figure 1. Percentage of publications of graphene in cancer fight (2008 to 
November 2014). 
 
Photothermal therapy is the second biggest por-
tion of works here analyzed with a portion of 32% 
(Figure 2A). In this context the material become at-
tractive since it has a large surface area, is lightweight, 
exhibits high strength and electrical conductivity and 
is capable of generating plasmon, fluorescence, and 
nonlinear emission [5]. In particular, phototermal 
therapy uses the capacity of graphene to absorb light 
in the near-infrared region (NIR). Irradiation at 808 
nm has been exploited, for example, in the ablation of 
many types of tumors both in vitro and in vivo in 
animal model [28]. 
Imaging application is in the third position in 
terms number of works related to cancer with 31% of 
the contributions (Figure 2A). Nanotehcnology im-
aging is very fruitful field and in the last few years has 
attracted many researchers aiming at testing the 
characteristics of numerous nanomaterials, such as 
carbon nanotubes [29] and quantum dots, as contrast 
agents [30] (Qdots) and graphene. Finally, a small part 
of the applications is occupied by photodynamic 
therapy (10%). The Venn diagram (Figure 2B), also 
shows 18 studies that used graphene for combining 
imaging and other cancer therapy, which further con-
firms and emphasizes the interest on this nano-
material for cancer diagnosis and therapy at the same 
time. The works on graphene as theranostic tool cover 
the 27%. 
Indeed, part of the works herein cited cover the 
use of imaging (ultrasonography, positron electron 
tomography (PET), fluorescent imaging) combined to 
one or more therapeutic action at the same time as 
showed in the Venn diagram (Figure 2B).  
 
 
Figure 2. Status of Graphene publications in the last 7 years for 
cancer fight. A) Percentage of manuscripts based on the applications 
against cancer. B) Venn diagram based on the main applications (Drug 
Delivery, Phototermal therapy, Photodynamic therapy, Imaging). In the red 
round the theranostic studies. 
 
We then decided to focus on the different types 
of cancer taken into consideration (Figure 3). Breast 
cancer is the most studied with a 35% of publications. 
Breast cancer is the most frequently diagnosed cancer 
in the world and the leading cause of cancer death in 
women, accounting for 25% (1.63 millions) of the total 
new cancer cases and 6,4% (0.522 millions) of the total 
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cancer deaths in 2012 [31]. About half of the breast 
cancer cases and 60% of the deaths are estimated to 
occur in Asian countries such as Iran, India and Qatar 
[2]. The second biggest portion is occupied by cervical 
cancer with a 23% of the total cases. Liver cancer is 
studied by 9% of the studies and the other cancers 
such as lymphoma, glioblastoma, glioma lung cancer, 
colon cancer, prostate cancer, brain cancer, pancreatic 
cancer and skin cancer takes the remaining part of the 
pie, with a range from 1% to 8% (Figure 3).  
 
 
Figure 3. Overview on different type of cancer treated with 
graphene. Manuscripts percentages per type of studied cancer. 
 
Drug and Gene Delivery 
In recent years graphene and the other members 
of the family including GO and reduced GO (rGO) 
have been investigated for biological and biomedical 
applications thanks to their possible biocompatibility 
[32]. Moreover, the extremely large surface area of the 
material, with every atom exposed on its surface al-
low ultra-high drug and gene loading efficiency [27]. 
All these properties make graphene an optimal can-
didate as drug carrier and gene delivery system as 
reported in table 1 [15, 32-92].  
The good drug loading ability of graphene en-
couraged many researchers to explore it in many dif-
ferent types of cancer. According to the general trend, 
the most studied tumor, with 31% of the total works, 
is breast cancer (Figure 5A) [15, 32, 34, 36, 39-41, 43, 
45, 49-51, 58, 65, 66, 72, 81, 86, 89, 92], followed by 
cervical cancer [35, 37, 42, 43, 52-54, 59, 63, 67, 68, 77, 
78, 82, 89] and liver cancer [44, 55, 72-75, 79, 85, 88] 
with 23% and 10% respectively. 
Other cancer types such as Burkitt’s lymphoma 
[33], colon cancer [34, 70, 71, 78, 91], prostate cancer 
[35, 64, 87], lung cancer [43, 56, 63, 76, 80, 87], skin 
cancer [57, 60], brain cancer [20, 38, 46-48, 61, 62], 
glioma [90] and glioblastoma [72] were studied under 
different drug treatment conjugated with graphene or 
graphene oxide.  
Drug Delivery 
As previously mentioned, drug delivery is the 
first application of graphene in terms of number of 
studies. We found 61 works that used graphene for 
drug and gene delivery alone or combined with other 
types of modalities to treat cancer (Figure 2B), such as 
PTT (10 works), PDT (3 works), and in imaging (13 
works). A big challenge in this perspective is to per-
form a good drug functionalization. Indeed, different 
approaches have been applied to load drug molecules 
onto graphene by different binding strategies. Many 
studies used polyethylene glycol (PEG) to increase the 
biocompatibility and physiological stability of gra-
phene or graphene oxide and subsequently load an-
ticancer drugs via non covalent interaction [32]. Liu et 
al. [47] functionalized the surface of GO-PEG with 
different ligands such as transferrin and doxorubicin 
(DOX) to target brain tumors. The conjugated 
nanosystems with trasferrin and doxorubicin dis-
played a greater intracellular delivery efficiency and 
stronger cytotoxicity against glioma. 
Regarding GO, it is certainly more investigated 
compared to pristine graphene for drug delivery 
purposes. Zhang et al. [15] proposed a very innova-
tive approach to exploit functionalized GO in bio-
medical research. The authors used first sulfonic acid 
groups functionalization (to make GO stable in phys-
iological solutions) followed by covalent binding of 
folic acid targeting specifically MCF-7 cells, a human 
breast cancer cell line expressing folic acid receptors. 
They demonstrated that this system loaded with two 
anticancer drugs (DOX and camptothecin) showed 
specific targeting MCF-7 cells and a remarkably high 
cytotoxicity compared to the material only loaded 
with one of the two drugs.  
DOX is a widely used chemotherapy agent and it 
can be loaded onto graphene via simple π−π stacking 
with high efficiency, resulting very promising to tar-
get the cancer. Thanks to this behavior, 31 studies 
were performed aiming at the delivery of DOX by 
graphene (Figure 4) [33, 36, 39, 42, 47, 49, 50, 53, 54, 61, 
63, 64, 68, 69, 74, 75, 77, 81-85, 87, 88, 90-92]. One of 
these studies used GO as a potential alternative to 
cross blood brain barrier in order to destroy cancer 
cells by the action of DOX [47]. Another approach 
used by Zhang et al. [36] evidenced the possibility of 
GO-PEG-DOX conjugate to combine the local specific 
chemotherapy with external near-infrared (NIR) 
photothermal therapy, which significantly improved 
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the therapeutic efficacy of the cancer treatment. 
Moreover, GO was used to load two or more drugs 
onto its surface at the same time [15, 33, 44, 68].  
We found camptotecin (CPT) as the second most 
conjugated drug to graphene (Figure 4). Sahoo et al., 
for example, described GO–poly(vinyl alcohol) (PVA) 
as drug carrier for CPT via non covalent interactions 
[32]. GO–PVA–CPT exhibited higher cytotoxic activ-
ity versus cancer cells compared to CPT alone. A lot of 
drugs were used in multiple conjugations with gra-
phene such as camptothecin [32, 66], 
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) [38], a 
commercial chemotherapeutic drug for treating ma-
lignant brain tumors, tamoxifen citrate [43], elsino-
chrome A [44], adriamycin [40], β-lapachone [41], lu-
canthone [72], paclitaxel [56, 76], anastrozole [65], 
5-fluorouracil [55], epirubicin [48, 62], curcumin [68], 
gambogic acid [86] ellagic acid [34], oxaliplatin (OXA) 
[91], cisplatin [91] and thermosensitive nanogel [64]. 
All these studies showed a great improvement in 
therapeutic efficacy when the drugs were loaded onto 
graphene. These promising data underline also the 
abilities of graphene as chemosensitizer. In this re-
gard, Chen et al. tested GO with different drugs (DOX, 
CPT, OXA and cisplatin (CDDP)) for the treatment of 
colon cancer cells (CT26 cells). They have shown that 
GO tested together with CDDP dramatically de-
creased the cell viability compared to the CDDP alone 
on resistant cells. The authors attributed this behavior 
to the capacity of GO to induce moderate levels of 
autophagic flux and also to potentiate nuclear import 
of the autophagy marker LC3 and CDDP [70, 91].  
 
 
Figure 4. Analysis of the amount of publications of graphene in drug 
delivery applications based on type of loaded drugs. 
 
Gene delivery 
Graphene-based materials have been also widely 
used for gene therapy as smart gene (siRNA, dsDNA 
and antisense oligonucleotides) carriers, for their po-
tential in the treatment of gene related diseases in-
cluding cancer [35, 51, 57, 71, 89]. Zhi et al., for exam-
ple, successfully used GO for co-delivery of drug 
(adriamicin) and siRNA against miRNA-21 (an-
ti-miR-21) that is responsible of multidrug resistance 
in breast cancer cells. They found that the treatment 
with GO as a carrier of chemotherapeutic drugs and 
siRNA is favorable for the treatment of drug resistant 
cancers restoring the chemosensitivity of anticancer 
drugs [51]. Another remarkable study performed by 
Yin et al. focused on melanoma [57], an aggressive 
disease characterized by a complex etiology where 
immunotherapy and targeted therapy seems to be 
promising ways to fight it [93, 94]. In this context, the 
authors evidenced the use of GO as a carrier of plas-
mid-based Stat3 siRNA. Their results indicated sig-
nificant regression in tumor growth and tumor weight 
after treatment without any collateral toxicity in vivo 
mouse model [57].  
Photothermal Therapy 
We found that the second most studied applica-
tion is the photothermal therapy (PTT) (Figure 2A). 
Recent publications have shown the interesting po-
tential of GO for PTT applications (see Table 1) [28, 
36, 61-64, 81-84, 95-109]. PTT has been reported either 
alone [95, 98, 99, 105, 108-110] or in combination with 
drugs [36, 61, 62, 64, 82, 104, 111] or with PDT [102, 
103, 106] or in both (Figure 2B). Photosensitizing 
agents are employed in PTT to generate heat from 
light absorption, leading to photoablation of cancer 
cells and subsequent cell death. To avoid nonspecific 
heating of healthy cells, photosensitizers must show 
absorption in the near-infrared region [112] and se-
lective uptake in cancerous cells over normal cells. 
Deep penetration and negligible nonspecific photo-
thermal heating in the NIR window are due to the 
transparency and low absorption of light by tissues in 
this optical window. Nowadays, a lot of nanomateri-
als are under investigation for their high optical ab-
sorbance in NIR for PTT including gold nanoshells 
[113], gold nanorods [114], gold pyramids [115], sin-
gle-walled carbon nanotubes (SWCNTs), and mul-
ti-walled carbon nanotubes (MWCNTs) [116]. Robin-
son et al. [95] used rGO non covalently PEGylated and 
conjugated to a peptide for targeting and selective 
photoablation of cancer cells at a low doses. Abdo-
lahad et al. [99] used rGO linked to the aromatic rings 
of green tea. Green tea is well known for its possible 
anticancer activity; indeed its polyphenol groups 
could be bound to cancer cell surface receptors. One 
of the important agents for this binding process is 
epigallocatechin gallate, the main polyphenol in green 
tea, which binds to the cancer cell surfaces. Thanks to 
the properties of green tea, the authors used low 
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concentration of reduced GO-green tea and had ap-
plied laser power in the PTT of colon cancer cells to 
obtain also high ablation efficiency [99]. It is also in-
teresting to note that 7 studies [28, 84, 97, 100, 101, 107, 
117] (Figure 2B) evidenced the use of graphene at the 
same time for imaging and PTT. Bian et al. [84] used 
graphene Au nancrystals for combining PTT with 
imaging and DOX delivery against breast cancer cells. 
They performed a controlled release of DOX mole-
cules from graphene nanocrystals through NIR heat-
ing, this system significantly reduced the possibility 
of side effects compared to general chemotherapy. 
As for drug delivery applications, the most 
studied tumor for PTT graphene-based treatment is 
breast cancer with the 42% of the works [28, 36, 81, 96, 
98, 100, 102, 104], followed by cervical cancer (26%) 
(Figure 5B) [37, 63, 82, 101, 103, 105, 106]. The other 
cancers treated with graphene in PTT modality com-
prise brain cancer (10%) [61, 62, 95] and lung cancer 
(7%) [63, 104]. The remaining 15% of studies [64, 99, 
108, 109] focus on prostate, pancreatic skin, colon and 
gastric cancer (Figure 5B).  
We found a growing interest in graphene breast 
cancer applications. Zhue et al. [118] i.e. discovered 
that GO was able to selectively down-regulate 
PGC-1α in breast cancer cells with a consequent inhi-
bition of ATP production. Furthermore, GO was able 
to impair the assembly of the F-actin cytoskeleton, 
which are required for the migratory and invasive 
phenotype of breast cancer. Taken together these ef-
fects of GO on cancer cell metastasis may allow the 
development of a new approach to treat metastatic 
breast cancer. The strong optical absorbance of the 
material in the NIR window prompted many scien-
tists to test this property in PTT against breast cancer 
[28, 36, 81, 96, 98, 100, 102, 104]. 
Yang et al. [28] reported the first experiments on 
this area using a GO-PEG for in vivo PTT and imag-
ing. The imaging modality revealed high uptake of 
graphene in several xenograft tumor mouse breast 
cancer models; a robust optical absorbance, an ul-
tra-efficient tumor ablation after intravenous admin-
istration under low-power NIR laser irradiation was 
achieved. No significant side effects were detected 
reporting the first success in using carbon nano-
materials for efficient in vivo PTT by intravenous 
administration. 
 
 
Figure 5. Paper analysis in terms of percentage of manuscripts divided by type of applications and type of cancer. 
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In the context of cervical cancer, Bai et al. [82] 
demonstrated that the combination of PTT and drug 
delivery, can be a potential treatment in the battles 
against cancer. The authors developed a synergistic 
therapy based on CuS nanoparticles decorated with a 
PEGylated GO. GO-PEG/CuS had high storage ca-
pacity for DOX and a high photothermal conversion 
efficiency achieving the ablation of cervical tumor in 
vitro and in vivo.  
Moreover, Zhang et al. [36] described the use of 
GO-PEG-DOX conjugate to improve the ablation of 
tumor both in vitro and in vivo. Indeed, the ability of 
the GO-PEG-DOX complex to combine the local spe-
cific chemotherapy with external NIR PTT signifi-
cantly improved the therapeutic efficacy of the cancer 
treatment. Compared with chemotherapy or PTT 
alone, the combined treatment demonstrated that the 
synergistic effect result in a higher therapeutic effica-
cy. Furthermore, as shown in the Venn diagram dif-
ferent works successfully used graphene for the com-
bination of PTT and imaging modalities (Figure 2B) 
[28, 84, 97, 100, 101, 107]. 
Photodynamic Therapy 
Graphene in the very last few years has been also 
tested as agent in photodynamic therapy thanks to its 
physical properties [60, 80, 103, 106, 119]. However, 
despite PDT is an FDA approved modality for the 
local treatment of a wide variety of tumor diseases, 
such as esophageal cancer and lung cancer [120], the 
number of works that used graphene in PDT are still 
very few, only 10% of the total (Figure 2A) [37, 60, 80, 
103, 106, 110, 119, 121].  
Otherwise, graphene was used in concert with 
PDT and imaging in 2 studies (Figure 2B) carried out 
by Sahu et al. [103] and Gollavelli et al. [106] giving 
new input for future studies on the use of the material 
for targeting and killing cancer cells also with PDT.  
Interestingly, differently from the other applica-
tions, 42% of the works in PDT focused on cervical 
cancer (Figure 5c). The other types of cancer explored 
were breast cancer and gastric cancer. PDT is based on 
photosensitizers sensitive to light upon suitable irra-
diation that produces reactive oxygen species (ROS), 
such as singlet oxygen, free radicals, or peroxides, 
inducing cytotoxicity. Compared with chemotherapy 
or radiotherapy, PDT shows relatively minimal side 
effects and improves tumor specific killing [122].  
Despite the few studies in this field, all cited 
works described the efficient capacity of the carbon 
material to be loaded with different types of photo-
sensitizers with a high action on cancer cell thanks to 
the PDT approach [80, 103, 123]. Zhou et al. [80] for 
example have combined GO with hypocrellin A pro-
posing it as a new second-generation photosensitizer. 
However, the loading of GO with hypocrellin A im-
proved the hydrosolubility but reduced the anticancer 
activity. To solve this problem, GO was co-loaded 
with a second anticancer agent to perform at the same 
time two anticancer treatments. Their results showed 
that the combination of two therapies exhibited a 
synergistic antiproliferative effect compared with 
PDT and chemotherapy alone. The majority of the 
analyzed works combined PDT with other types of 
anticancer strategies [103, 106]. In the work of Sahu et 
al. [103] GO was non-covalently functionalized with 
pluronic block copolymer and complexed with meth-
ylene blue, a hydrophilic and positively charged 
photosensitizer to combine PDT and PTT versus can-
cer. The release of the photosensitizer from GO sur-
face was pH-dependent and an acidic condition in-
creased the release rate considerably. This nanocom-
plex showed enhanced uptake by cancer cells than 
normal cells and, when cells were irradiated with se-
lective NIR laser lights, it induced significant cell 
death. This work showed the potential of GO for a 
synergistic combination of PDT with PTT. On the 
other hand, Huang et al. [119] described the GO ab-
sorption of the photosensitizer named Chlorin e6 
(Ce6). GO-Ce6 accumulation in tumor cells led to a 
remarkable photodynamic efficacy on cancer gastric 
cells upon irradiation. Overall, the works we de-
scribed showed the great potential of graphene in 
PDT alone or in concert with other cancer treatments. 
Imaging 
In the context of imaging, graphene have been 
explored to improve the diagnosis and also the 
treatment of cancer with the aim to avoid several side 
effect related with the current use of toxic chemicals 
as contrast agents. Most fluorescent molecular dyes 
(i.e. Qdots), because of their intrinsic toxicity, are not 
suitable for the diagnosis in many cancer patients that 
may already have chemotherapy-related damages to 
liver or kidney [124]. The excellent photostability of 
graphene-based nanomaterials makes them suitable 
for many biological imaging techniques such as pho-
toacoustic imaging (PI), ultrasonography (US), mag-
netic resonance imaging (MRI), computed tomogra-
phy (CT) and optical imaging applications (see table 
1) [28, 33, 35, 45, 58, 59, 77, 78, 85, 87, 88, 96, 97, 
100-102, 111, 125, 126]. The optical imaging potential 
of graphene was well studied by many reports [88, 
125]. Gao et al. reported a GO-based fluorescent 
magnetic hybrid for loading and delivery of Doxoru-
bicin. They applied GO for in vitro tumor cellular 
imaging and showed high uptake of GO into hepato-
cellular carcinoma cell line with a strong fluorescence. 
These data have evidenced the GO abilities as an op-
tical imaging tool [88]. Regarding ultrasonography, 
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our group showed in a previous study that GO has 
good echogenic properties with a promising future in 
the scenario of ultrasound contrast agents [29]. 
Moreover graphene could be useful also in MRI. The 
magnetic graphene complexes that could be useful for 
MRI and, at the same time, for other imaging or 
therapy modalities are of particular interest [87, 90, 97, 
106, 117, 127]. Wang et al. used magnetic a graphene 
complex for metastatic pancreatic cell diagnosis in the 
lymphonodes. At the same time they were able to 
directly guide the PTT therapy against cancer cells 
[117]. Gollavelli et al. used the ability of magnetic 
graphene as a potential theranostic nanocarrier for 
MRI and fluorescence dual modality imaging and for 
PDT and PTT [106]. Furthermore, it is interesting to 
evidence the potential of graphene as an in vitro de-
tection tool (IVD); Zhang et al. developed a new col-
orimetric assay for the direct detection of cancer cells 
using graphene as a signal transducer [128]. Moreover 
in the IVD field, graphene was also used as a biosen-
sor for molecular marker analysis in cancer diagnosis 
[129]. 
We found 31% of the total studies used graphene 
for cancer imaging and this percentage is expected to 
grow fast in few years (Figure 2A). Furthermore, 
graphene was almost always used in imaging with the 
therapy approaches cited before (Figure 2B). Thus, 
many authors, thanks to the good imaging character-
istics of graphene, combined with encouraging results 
diagnosis with therapy (i.e. drug delivery or pho-
totermal therapy) [58, 59, 96, 106, 111, 117, 126]. 
Moreover, the majority of the works addressed breast 
cancer as target model cancer with a 60% of the total 
studies (Figure 5D). In accordance with the other ap-
plications, the second most investigated tumor for 
imaging was cervical cancer (Figure 5D). Shi et al., 
[58] for example, studied the specific targeting of 
functionalized rGO conjugates to murine breast can-
cer in vivo. The authors used rGO loaded with a spe-
cific antibody to endoglin (CD105) for active tumor 
targeting in living subjects using positron emission 
tomography (PET) imaging. Hu et al. [96] used gra-
phene presenting multiple functions into a single 
system: imaging, drug delivery and photothermal 
therapy. In this study NIR potential of GO was com-
bined with the good fluorescence of Qdots. To avoid 
the fluorescence quenching induced by GO, a spacer 
was inserted between GO and the dye. This nanosys-
tem was able to kill breast cancer cells and also served 
as optical indicator to monitor the therapeutic pro-
gress by fluorescence imaging. Otherwise, the com-
binations of GO and Qdots need more studies for its 
biomedical use in therapy to better understand the 
possible toxicity of this nanoconjugate. Nevertheless, 
the use of graphene and Qdots is frequently investi-
gated to improve the imaging ability of graphene. 
Among the works that combined imaging and PTT, 
Yang et al. [28] published one of the first studies that 
used this strategy. They found in vivo fluorescence 
imaging revealed surprisingly high tumor uptake of 
graphene in several xenograft tumor mouse models. 
Moreover, to combine the two applications, authors 
showed a strong optical absorbance in the 
near-infrared region for in vivo PTT with a good ab-
lation of cancer cells. 
The majority of research groups joint the imag-
ing properties with the drug delivery applications. 
Chen et al. used as well as Hu SH et al. graphene 
conjugated with Qdots for targeted cancer fluorescent 
imaging, tracking and monitoring the delivery of 
drug into the cancer site [59, 96].  
Cornelissen et al. [126] used GO coupled with 
anti-Her2 antibody, amonoclonal antibody for the 
treatment of breast cancer, and radiolabeled it with 
[In111]-benzyl-diethylene-triaminepenta acetic acid via 
π-π-stacking for targeted and functional imaging. This 
construct [103]has shown an improvement in the tar-
geting and therapy of breast cancer cells in mouse 
model compared to anti-Her2 alone. Indeed, the au-
thors showed a clear in vivo visualization of the tu-
mor using single-photon emission computed tomog-
raphy. 
Combined therapy and theranostics  
All great potential of graphene in many cancer 
therapies (drug delivery, PTT and PDT) encouraged 
many authors to test graphene also combining dif-
ferent approaches for cancer treatment (see table 1) 
[36, 37, 60-64, 80-84, 89, 92, 102, 106]. 
Among this type of works, the higher number of 
studies (11 in total), herein analyzed, used graphene 
for combining drug delivery and PTT. Thanks to 
graphene properties, the authors combined both 
therapies in a single system enhancing the efficacy of 
the single modality. A clear example of these en-
hancements is well explained in the work of Feng et al. 
were the authors used GO as a carrier for siRNA and 
pDNA [89]. They showed that PTT induced local 
heating and accelerated intracellular trafficking of GO 
vectors, opening interesting new applications for 
combined therapies [89]. The same group, in another 
work, combined the DOX function with the PTT 
treatment. They showed a remarkably improved cell 
killing for drug-resistant cancer cells in comparison 
with free DOX. Other therapies, such as PTT and PDT, 
were combined only in three works herein reported. 
Previously, we described the works of Sahu et al. and 
Gollavelli et al. [103, 106]; their findings underlined 
the potential of GO for a synergistic combination of 
PDT with PTT.  
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Drug delivery and PDT were combined in three 
works [37, 60, 80]. Zhou et al. [80] have combined GO 
with hypocrellin A and Camptothecin. Their results 
showed that the combination of drug delivery and 
PDT exhibited a synergistic antiproliferative effect 
compared with PDT and drug delivery alone. All 
works taken in consideration on combined therapies 
displayed very interesting possibilities to reach the 
ultimate purpose to fight cancer.  
The great and innovative property of graphene is 
its good imaging characteristics that has prompted 
many Authors to combined imaging with one-therapy 
applications (i.e. drug delivery or phototermal ther-
apy as shown in figure 2B) [28, 33, 35, 45, 58, 59, 77-79, 
85, 87, 88, 90, 96, 97, 100, 101, 107, 117, 121]. The larg-
est number of studies herein cited and commented 
(12) combined the imaging properties of graphene 
with the good loading ability in drug delivery and 
gene delivery (see table 1). The first study that used 
this approach was Sun et al. they explored for the first 
time the ability of graphene as a theranostics tool in-
deed they found that the novel graphitic nanostruc-
tures, combined with multi-functionalities including 
biocompatibility, photoluminescence and drug load-
ing and delivery, suggest promising applications of 
graphene materials in biological and medical areas 
[33]. This previous report open the way for all the 
further study that improve this findings improving 
the ability of graphene also as a combined materials. 
Thanks to graphene also PTT and PDT were com-
bined with imaging, we found 8 works herein ana-
lyzed that used this strategy. Yang et al. was the first 
study that used graphene for PTT and imaging for 
give the successful ablation of breast cancer [28]. All 
these studies reached the purpose to fight cancer more 
effectively showing graphene as one of the most 
promising nanomaterial to reach the goal of cure 
cancer. On the other hand, three additional works [84, 
102, 106] used graphene for combined therapies and 
imaging. This type of approach is expected to grow 
fast in the next years, suggesting an exponentially 
growing success of graphene for more theranostic 
applications. 
Conclusion and perspectives  
In summary, all studies herein analyzed under-
line the potential of graphene in the theranostic field 
that allow concomitantly the diagnosis and the ther-
apy of a tumor area.  
Many works pointed out that different biomol-
ecules such as siRNA, DNA and anticancer drugs 
such as doxorubicin can be loaded onto the surface of 
graphene for gene transfection and drug delivery. 
Moreover, the property of graphene to adsorb light in 
the NIR region has been tested from many research 
groups in phototherapy for in vivo and in vitro cancer 
treatment. This action combined with drug delivery 
and imaging could be used in a synergic treatment of 
cancer, increasing the targeted killing with less im-
pairment of healthy cells. Furthermore, many studies, 
thanks to the graphene optical properties and the 
loading ability, tested this nanomaterial also in the 
phothodynamic treatment. We showed that graphene 
alone or conjuged with various inorganic nanoparti-
cles such as Qdots, gold nanoparticles, magnetic iron 
nanoparticles and also loaded with fluorescent dye 
have all the potential to be used in many types of 
imaging such as optical imaging, ultrasonography, 
nuclear imaging and MRI. The great potential of 
graphene is the ability to provide at the same time 
many different cancer therapies joined to imaging 
make graphene one of the most promising next gen-
eration theranostic agents. Otherwise, further studies 
are still needed for the clinical translation of graphene 
in the context of cancer. In particular, it would be 
necessary to perform further investigations to prove 
the absence of toxicity and other side effects for 
healthy cells. For example, we previously noted the 
lack of studies focused on carbon materials interaction 
with immune cells [7, 130-132]. 
Furthermore, there are many discrepancies be-
tween the scientists in the context of toxicity of gra-
phene. Several works reported a good biocompatibil-
ity and no cellular damage after exposure to gra-
phene. However, other authors have evidenced cell 
toxicity with the enhancing of apoptosis and necrosis 
[133, 134]. These variances in the scientific findings are 
especially due to the differences in size dimensions, 
functionalization and purification of the employed 
graphene samples.  
Another point of interest is also related to gra-
phene elimination from the living systems. Indeed 
how graphene is degraded and excreted is still not 
very well explained. 
A better understanding of graphene and its de-
rivatives behaviors in biological systems is needed to 
improve its performances also for theranostic appli-
cations. Although not only toxicology should be better 
addressed, but also the functionalization modalities 
and the conjugations of graphene that are important 
for its biocompatibility and pharmacokinetic profiles.  
Here we give many interesting perspectives for 
new graphene-based studies about the treatment and 
diagnosis of various types of cancers, and especially 
breast cancer.  
We believe that graphene is one of the most 
promising materials destined to change our day life 
and the future treatment and diagnosis of cancer.  
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